Brief: Adagene Announces FDA Clearance Of Ind For Phase 1B/2 Trial Of Anti-CTLA-4 Monoclonal Antibody Adg116
29/11/2021 21:07
Nov 29 (Reuters) - Adagene Inc 978y.F :
* ADAGENE ANNOUNCES FDA CLEARANCE OF IND FOR PHASE 1B/2
TRIAL OF
ANTI-CTLA-4 MONOCLONAL ANTIBODY ADG116 IN COMBINATION THERAPY
WITH ANTI-PD-1 ANTIBODY PEMBROLIZUMAB
Source text for Eikon: ID:nGNX8KB301
Further company coverage: 978y.F
Recent news on Adagene
See all newsBrief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate
Brief: Adagene Inc - Partners With Conjugatebio For Antibody Drug Conjugate Development
Brief: Adagene Announces Up To $25 Million Strategic Investment From Sanofi